
    
      For Group A, after screening, eligible subjects will be treated from day 1 and followed up
      for 24 months.

      For Group B, the study includes two phases as follows:

      Main study phase: It is randomized, evaluator-blinded and no-treatment controlled. After
      screening, all eligible subjects will be randomized either to the Treatment Group or the
      Control Group in a 2:1 ratio. All the subjects will be followed up for 12 months.

      Extension study phase: After the main study phase, the Treatment Group will be followed up
      for additional 12 months.

      Each subject assigned to Group A and Treatment Group will receive up to 4 injection sessions
      with 5(Â±1) weeks intervals.

      Subjects assigned to the Control Group will not receive treatment during the study.
    
  